Long‐term outcomes of thalidomide in refractory Crohn's disease

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|41|5|429-437

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.41, Iss.5, 2015-03, pp. : 429-437

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long‐term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 588-595

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial: is thalidomide a good option for patients with refractory Crohn's disease?

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 8, 2015-04 ,pp. : 785-786

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial: is thalidomide a good option for patients with refractory Crohn's disease? Authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 8, 2015-04 ,pp. : 786-786

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term treatment outcomes in Gaucher disease

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. S1, 2015-07 ,pp. : S19-S24

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long‐term therapeutic effectiveness of maintenance enteral nutrition for Crohn's disease

By  

PEDIATRICS INTERNATIONAL, Vol. 57, Iss. 2, 2015-04 ,pp. : 276-280

John Wiley & Sons Inc

Access to resources Recommend Favorite